Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2- Breast cancer: A network meta-analysis of 19 RCTs

Breast J. 2020 Sep;26(9):1862-1866. doi: 10.1111/tbj.13780. Epub 2020 Feb 9.
No abstract available

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Female
  • Humans
  • Network Meta-Analysis
  • Phosphatidylinositol 3-Kinases*
  • Protein Kinase Inhibitors
  • Receptor, ErbB-2
  • TOR Serine-Threonine Kinases

Substances

  • Protein Kinase Inhibitors
  • MTOR protein, human
  • Receptor, ErbB-2
  • TOR Serine-Threonine Kinases